Recent studies have also shown aberrant higher expression and activation of ZIP7 in some malignant tumors, including tamoxifen-resistant breast cancer, esophageal cancer, lung cancer, prostate cancer, gastric cancer, and hepatocellular carcinoma (HCC)7–9. The gene discussed is SLC39A7; the disease is hepatocellular carcinoma.